References
1- Döhner H, Estey E, Grimwade D et al. Diagnosis and Management of AML in Adults - 2017 ELN
Recommendations. Blood. 2017; 129: 424-447.
2- Papadantonakis N, Advani AS. Recent advances and novel treatment paradigms in acute lymphocytic
leukemia. Ther Adv Hematol. 2016; 7:252-269.
3- Gragert L, Eapen M, Williams E et al. HLA match likelihoods for hematopoietic stem-cell grafts in the
U.S. registry. N Engl J Med. 2014; 371:339-48.
4 - Powles RL, Morgenstern GR, Kay HE et al Mismatched family donors for bone-marrow transplantation
as treatment for acute leukemia. Lancet. 1983;1:612-5.
5- Aversa F, Terenzi A, Tabilio A et al. Full haplotype-mismatched hematopoietic stem-cell
transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol.
2005;23:3447-54.
6- Luznik L, O'Donnell PV, Fuchs EJ. Post-Transplantation cyclophosphamide for tolerance induction in
HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012; 39:683-93.
7- McCurdy SR, Kanakry JA, Showel MM et al. Risk-stratified outcomes of nonmyeloablative HLA-haploidentical
BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015;125:3024-31.
8- Raiola AM., Dominietto A., Ghiso A. et al. Unmanipulated haploidentical bone marrow transplantation
and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative
conditioning. Biol Blood Marrow Transplant 2013; 19: 117-122.
9. Lee CJ, Savani BN, Mohty M. et al. Haploidentical hematopoietic cell transplantation for adult acute
myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society
for Blood and Marrow Transplantation. Haematologica. 2017; 102: 1810–1822.
10. Imus PH, Tsai HL, Luznik L, et al. Haploidentical transplantation using posttransplant
cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019; 3: 2608–2616